Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Most cancers retain functional retinoblastoma (Rb) protein, suggesting potential sensitivity to CDK4/6 kinase inhibitors.
• CDK4/6 inhibitors have demonstrated efficacy in breast cancer and lymphomas, but their broader applicability across Rb-positive tumors remains underexplored.
• A systematic evaluation of tumor-type specific sensitivities and molecular response determinants to CDK4/6 inhibition is lacking.

Purpose of the Study:

• To identify additional Rb-positive cancer types that may benefit from CDK4/6 inhibitor therapy.
• To define molecular characteristics associated with sensitivity to CDK4/6 inhibition.
• To investigate the role of D-cyclin levels and specific mutations in determining response.

Main Methods:

• Systematic survey of cancer cell lines and patient-derived xenografts for sensitivity to CDK4/6 inhibition.
• Genomic profiling to identify aberrations correlated with D-cyclin pathway activation.
• Analysis of CCND1 gene and its regulatory regions, including 3'UTR mutations.

Main Results:

• A subset of Rb-positive cancers demonstrated high sensitivity to CDK4/6 inhibition.
• Genomic alterations known to increase D-cyclin levels were associated with sensitivity.
• A recurrent mutation in the CCND1 3'UTR was identified in endometrial cancer, leading to increased CCND1 expression and heightened sensitivity.

Conclusions:

• CDK4/6 inhibitors represent a promising therapeutic strategy for a broader range of Rb-positive cancers beyond breast cancer and lymphomas.
• Genomic aberrations affecting D-cyclin levels are key determinants of response to CDK4/6 inhibitors.
• Endometrial cancer, particularly cases with CCND1 3'UTR mutations, may be a responsive tumor type to agents like abemaciclib.